{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1390282680165615360.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.4993/acrt.18.73"}},{"identifier":{"@type":"URI","@value":"http://www.jstage.jst.go.jp/article/acrt/18/2/18_2_73/_pdf"}},{"identifier":{"@type":"NAID","@value":"130000400034"}},{"identifier":{"@type":"URI","@value":"https://search.jamas.or.jp/link/ui/2011336010"}}],"dc:title":[{"@language":"en","@value":"Appropriate interruption of cetuximab may balance efficacy and toxicity: a case of long-term treatment with FOLFIRI plus cetuximab"}],"dc:language":"en","description":[{"type":"abstract","notation":[{"@language":"en","@value":"A case of long-term treatment with FOLFIRI plus cetuximab was presented. A 77-year-old Japanese male was introduced FOLFIRI plus cetuximab as second line treatment. Although the CT revealed partial response, dermatologic adverse event was rather severe and eventually the case required cetuximab cessation. During the FOLFIRI without cetuximab period, CT evaluation revealed disease progression, but after the re-introduction of cetuximab, partial response was observed again. The course of this case would suggest the importance of appropriate cessation of cetuximab in order to balance the efficacy and toxicity, resulting in long treatment period like OPTIMOX strategy."}],"abstractLicenseFlag":"disallow"}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1410282680165615366","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105841"}],"foaf:name":[{"@language":"en","@value":"Matsui Takanori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615367","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105846"}],"foaf:name":[{"@language":"en","@value":"Kojima Hiroshi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1030003658549222016","@type":"Researcher","personIdentifier":[{"@type":"KAKEN_RESEARCHERS","@value":"20646682"},{"@type":"NRID","@value":"1000020646682"},{"@type":"NRID","@value":"9000021105851"}],"foaf:name":[{"@language":"en","@value":"Fujii Yuka"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Certified nurse in wound, ostomy and continence nursing, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615364","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105856"}],"foaf:name":[{"@language":"en","@value":"Yamada Tomohiro"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615360","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105860"}],"foaf:name":[{"@language":"en","@value":"Hirota Masashi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615363","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105864"}],"foaf:name":[{"@language":"en","@value":"Uemura Takanori"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615361","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105868"}],"foaf:name":[{"@language":"en","@value":"Fujimitsu Yasunobu"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of gastroenterological surgery, Aichi cancer center Aichi hospital"}]},{"@id":"https://cir.nii.ac.jp/crid/1410282680165615362","@type":"Researcher","personIdentifier":[{"@type":"NRID","@value":"9000021105872"}],"foaf:name":[{"@language":"en","@value":"Sakamoto Junichi"}],"jpcoar:affiliationName":[{"@language":"en","@value":"Department of Social-Life Science, Nagoya University Graduate School of Medicine"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"13446835"},{"@type":"EISSN","@value":"18805469"},{"@type":"CODEN","@value":"ACRTCO"}],"prism:publicationName":[{"@language":"en","@value":"Annals of Cancer Research and Therapy"},{"@language":"ja","@value":"Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ"},{"@language":"en","@value":"Ann. Cancer Res. Therap."},{"@language":"en","@value":"ACRT"},{"@language":"ja","@value":"Ａｎｎａｌｓ　ｏｆ　Ｃａｎｃｅｒ　Ｒｅｓｅａｒｃｈ　ａｎｄ　Ｔｈｅｒａｐｙ"}],"dc:publisher":[{"@language":"en","@value":"The Japanese Society of Strategies for Cancer Research and Therapy"},{"@language":"ja","@value":"日本癌病態治療研究会"}],"prism:publicationDate":"2010","prism:volume":"18","prism:number":"2","prism:startingPage":"73","prism:endingPage":"76"},"reviewed":"false","dcterms:accessRights":"http://purl.org/coar/access_right/c_abf2","url":[{"@id":"http://www.jstage.jst.go.jp/article/acrt/18/2/18_2_73/_pdf"},{"@id":"https://search.jamas.or.jp/link/ui/2011336010"}],"availableAt":"2010","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=FOLFIRI","dc:title":"FOLFIRI"},{"@id":"https://cir.nii.ac.jp/all?q=Cetuximab","dc:title":"Cetuximab"},{"@id":"https://cir.nii.ac.jp/all?q=Metastatic%20colorectal%20cancer","dc:title":"Metastatic colorectal cancer"},{"@id":"https://cir.nii.ac.jp/all?q=OPTIMOX","dc:title":"OPTIMOX"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1360292621493047168","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Health-Related Quality of Life in Patients With Advanced Colorectal Cancer Treated With Cetuximab: Overall and <i>KRAS</i>-Specific Results of the NCIC CTG and AGITG CO.17 Trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1361981470452533504","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Phase II study of an optimized 5-fluorouracil-oxaliplatin strategy (OPTIMOX2) with celecoxib in metastatic colorectal cancer: a GERCOR study"}]},{"@id":"https://cir.nii.ac.jp/crid/1362262943611464960","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer—A GERCOR Study"}]},{"@id":"https://cir.nii.ac.jp/crid/1363388845578180096","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial"}]},{"@id":"https://cir.nii.ac.jp/crid/1363670320387519232","@type":"Article","relationType":["references"],"jpcoar:relatedTitle":[{"@value":"Leucovorin and Fluorouracil With or Without Oxaliplatin as First-Line Treatment in Advanced Colorectal Cancer"}]}],"dataSourceIdentifier":[{"@type":"JALC","@value":"oai:japanlinkcenter.org:0035970423"},{"@type":"CROSSREF","@value":"10.4993/acrt.18.73"},{"@type":"CIA","@value":"130000400034"},{"@type":"OPENAIRE","@value":"doi_dedup___::cb31a79ffe20a47dd48db41a137ac290"}]}